118 related articles for article (PubMed ID: 3544497)
1. Evaluation of a new confirmatory assay for antibodies against lymphadenopathy-associated virus (LAV)/human T-lymphotropic virus type III (HTLV III).
Abb J
Vox Sang; 1986; 51(3):233-5. PubMed ID: 3544497
[TBL] [Abstract][Full Text] [Related]
2. Detection of acquired immunodeficiency syndrome (AIDS) retrovirus antibody by lymphadenopathy-associated virus (LAV) enzyme immunoassay in low- and high-risk populations.
Ragni MV; Lewis JH; Bracken M; Toth R; Stokes J; Steffensen DO
Transfusion; 1986; 26(3):299-301. PubMed ID: 3010516
[TBL] [Abstract][Full Text] [Related]
3. Laboratory and epidemiologic evaluation of an enzyme immunoassay for antibodies to HTLV-III.
Ward JW; Grindon AJ; Feorino PM; Schable C; Parvin M; Allen JR
JAMA; 1986 Jul; 256(3):357-61. PubMed ID: 3014173
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunoassay and enzyme-linked immunoassay of antibodies to the core protein (P24) of human T-lymphotropic virus (HTLV III).
Neurath AR; Strick N; Sproul P; Baker L; Rubinstein P; Stevens CE; Taylor P; Gallo RC; Gold JW; Lee YS
J Virol Methods; 1985 May; 11(1):75-86. PubMed ID: 2989312
[TBL] [Abstract][Full Text] [Related]
5. Importance of western blot analysis in predicting infectivity of anti-HTLV-III/LAV positive blood.
Esteban JI; Shih JW; Tai CC; Bodner AJ; Kay JW; Alter HJ
Lancet; 1985 Nov; 2(8464):1083-6. PubMed ID: 2865566
[TBL] [Abstract][Full Text] [Related]
6. Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.
Rook AH; Lane HC; Folks T; McCoy S; Alter H; Fauci AS
J Immunol; 1987 Feb; 138(4):1064-7. PubMed ID: 3027168
[TBL] [Abstract][Full Text] [Related]
7. Assessment of screening as a preventive technology: the example of HTLV-III/LAV antibody testing.
Ory HW; Koplan JP; Allen JR
Isr J Med Sci; 1986; 22(7-8):524-8. PubMed ID: 3640749
[TBL] [Abstract][Full Text] [Related]
8. How sensitive are the commercial assays for anti-HTLV III/LAV?
Oldham LJ; Moulsdale HJ; Mortimer PP; Tedder RS; Morgan-Capner P
J Med Virol; 1987 Jan; 21(1):75-9. PubMed ID: 3467026
[TBL] [Abstract][Full Text] [Related]
9. HTLV-III/LAV infection in hemodialysis patients.
Peterman TA; Lang GR; Mikos NJ; Solomon SL; Schable CA; Feorino PM; Britz JA; Allen JR
JAMA; 1986 May; 255(17):2324-6. PubMed ID: 3007792
[TBL] [Abstract][Full Text] [Related]
10. Performance evaluation of the Abbott HTLV III EIA, a test for antibody to HTLV III in donor blood.
Barrett JE; Dawson G; Heller J; Bairstow C; Fico R; Webber JS; Gutierrez R; Decker RH
Am J Clin Pathol; 1986 Aug; 86(2):180-5. PubMed ID: 3017089
[TBL] [Abstract][Full Text] [Related]
11. Non-Hodgkin's lymphoma, HTLV-III/LAV, and HTLV-III/LAV antibody in the wife of a man with transfusion-acquired AIDS.
Duncan ED; Miller HJ; McKeever WP
Am J Med; 1986 Nov; 81(5):898-900. PubMed ID: 3640579
[TBL] [Abstract][Full Text] [Related]
12. Limitations of enzyme immunoassay tests for detection of HTLV-III/LAV antibodies.
Lyons SF; McGillivray GM; Coppin AP; Schoub BD
S Afr Med J; 1985 Oct; 68(8):575-6. PubMed ID: 2996159
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus antibody screening in blood donors from India, Nigeria and Thailand.
Kühnl P; Seidl S; Ray V; Kulkarni AG; Mba EC; Chandanayingyong D
Vox Sang; 1987; 52(3):203-5. PubMed ID: 3300027
[TBL] [Abstract][Full Text] [Related]
14. [HIV (HTLV III/LAV) serology: experiences based on more than 42,000 tests].
Gschnait F; Schmidt BL; Schwarz T; Heinz FX; Kunz C
Wien Klin Wochenschr; 1987 Aug; 99(15):536-9. PubMed ID: 3310415
[TBL] [Abstract][Full Text] [Related]
15. Use of an enzyme immunoassay for detection of antibody to human immunodeficiency virus in low risk populations.
Peetoom F
Transfusion; 1986; 26(6):536-8. PubMed ID: 3535179
[TBL] [Abstract][Full Text] [Related]
16. Determination of antibodies against LAV/HTLV III: comparative evaluation of four different commercial test kits.
Abb J
AIDS Res; 1986; 2(2):93-7. PubMed ID: 3013224
[TBL] [Abstract][Full Text] [Related]
17. High prevalence and high titers of LAV/HTLV-III antibodies in healthy hemophiliacs in the midwestern United States.
Goldsmith JC; Dewhurst S; Hedenskog M; Casareale D; Volsky DJ
Am J Med; 1986 Oct; 81(4):579-83. PubMed ID: 3532787
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to human immunodeficiency virus (HTLV-III/LAV) in people from Lagos and Cross River States of Nigeria.
Okpara RA; Akinsete I; Williams EE; Schneider J; Wendler I; Hunsmann G
Acta Haematol; 1988; 79(2):91-3. PubMed ID: 3124480
[TBL] [Abstract][Full Text] [Related]
19. An immunoglobulin G capture assay (GACRIA) for anti-HTLV III/LAV and its use as a confirmatory test.
Parry JV
J Med Virol; 1986 Aug; 19(4):387-97. PubMed ID: 3018141
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunoassay and enzyme-linked immunoassay of antibodies directed against lymphadenopathy-associated virus (LAV) proteins larger than the core protein (P24).
Neurath AR; Strick N; Lee YS; Nilsen T; Baker L; Sproul P; Rubinstein P; Taylor P; Stevens CE; Gold JW
J Virol Methods; 1985 Oct; 12(1-2):85-92. PubMed ID: 3001122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
